Zynex Inc
NASDAQ:ZYXI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.19
13.74
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Zynex Inc
Total Receivables
Zynex Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Zynex Inc
NASDAQ:ZYXI
|
Total Receivables
$21.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
38%
|
CAGR 10-Years
16%
|
||
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
||
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
||
Stryker Corp
NYSE:SYK
|
Total Receivables
$3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
||
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$6.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
||
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
Zynex Inc
Glance View
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. The company is headquartered in Englewood, Colorado and currently employs 774 full-time employees. The company went IPO on 2002-11-27. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.
See Also
What is Zynex Inc's Total Receivables?
Total Receivables
21.6m
USD
Based on the financial report for Sep 30, 2024, Zynex Inc's Total Receivables amounts to 21.6m USD.
What is Zynex Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
16%
Over the last year, the Total Receivables growth was -35%. The average annual Total Receivables growth rates for Zynex Inc have been -4% over the past three years , 38% over the past five years , and 16% over the past ten years .